MIRA INFORM REPORT
|
Report Date : |
22.08.2011 |
IDENTIFICATION DETAILS
|
Name : |
ST PHARM CO., LTD. |
|
|
|
|
Formerly Known As : |
U-CHEM CO., LTD. |
|
|
|
|
Registered Office : |
1241-2, Jeongwang-dong, Siheung-si, Gyeonggi-do,
Korea, Zip Code 429-850 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Date of Incorporation : |
20.08.2008 |
|
|
|
|
Com. Reg. No.: |
303-81-52269 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Chemicals and Antibiotics |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment
Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
South Korea |
a1 |
a1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Basic
|
Company Name |
ST PHARM CO., LTD. (Korean Company Name : “에스티팜(주)”) |
|
Registered Address |
1241-2, Jeongwang-dong,
Siheung-si, Gyeonggi-do, Korea |
|
Zip Code |
429-850 |
|
Tel |
+82-31-499-3002 |
|
Fax |
+82-31-499-3001 |
|
E-mail |
|
|
Website |
|
|
Trading Address |
7FL., MSA Bldg., 891-43, Daechi-dong,
Gangnam-gu, Seoul, Korea |
|
Tel |
+82-2-527-6318 |
|
Fax |
+82-2-561-6006 |
|
Other Address |
Rm.505, JC Pharm Bldg., 745-2, Choji-dong,
Danwon-gu, Ansan-si, Gyeonggi-do, Korea |
|
Type |
Export/Import |
|
Industry |
Manufacture of Medicinal Chemicals and Antibiotics |
|
Main Business |
Zidovudine(API), Nucleoside API, NANA, DNA/RNA(Oligonucleotides),
Nucleoside Monomer(Amidite) |
|
Established (mm/dd/yyyy) |
08/20/2008 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs affecting the gastrointestinal
system(51170000) |
CEO’s
|
Name |
Lim Keun-Jo |
|
Address |
Suite 206-802, 654, Gaepo-dong,
Gangnam-gu, Seoul, Korea |
|
Date of Birth |
05/10/1959 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
1,060,000,000 |
||||||||||||
|
Employees |
171 |
||||||||||||
|
Formation |
Co., Ltd by shares A Company of Dong-A Socio Group |
||||||||||||
|
Bank Details |
Shinhan Bank-Samseong Central Branch |
||||||||||||
|
Corporate Registered No. |
154511-0039704 |
||||||||||||
|
Business Registered No. |
303-81-52269 |
||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 521819 |
||||||||||||
|
Shareholder Position |
|
||||||||||||
|
Company History |
08/20/2008 Incorporated as U-CHEM CO., LTD. 10/04/2010 Changed company name to the
present name 10/04/2010 Moved to the present HQ address
from 1507, Jungwon Industrial Complex, Dang-u-ri, Judeok-eup, Chungju-si,
Chungbuk, Korea 09/30/2010 Acquired Samchully Phram Co.,
Ltd.(110111-4241264) at 7FL., MSA Bldg., 891-43, Daechi-dong, Gangnam-gu, Seoul, Korea |
||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
President & CEO |
Mr. |
Lim Keun-Jo |
Male |
Korean |
08/20/2008 |
|
Director |
Mr. |
Kang Jung-Seok |
Male |
Korean |
06/10/2010 |
|
Director |
Mr. |
Cho Jin-Woo |
Male |
Korean |
06/10/2010 |
|
Auditor |
Mr. |
You Jong-Sik |
Male |
Korean |
06/10/2010 |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
28,920,009,000 |
67,155,928,000 |
973,613,000 |
|
|
2009 |
|
|
|
|
2008 |
|
|
|
The financials are
not available, and the Subject Company does not have any obligations to release
its financials to the public.
Financial Description
|
Authorized Capital(KRW) |
5,000,000,000 |
|
Paid-Up Capital(KRW) |
1,060,000,000 |
|
Total Issues Shares |
212,000(Common :127,000 / Preferable : 85,000) |
Products, Technologies, Services Description
|
Main Products & Services |
Medicinal Chemicals and Antibiotics |
Trade Partners & Competitors
|
Competitors |
YUHAN
CORPORATION(110111-0014409) 49-6, DAEBANG-DONG, DONGJAK-GU, SEOUL,
KOREA TEL:+82-2-828-0181 FAX:+82-2-828-0050 HANMI PHARM CO., LTD.(110111-0014409) 893-5, HAJEO-RI, PALTAN-MYEON, HWASEONG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-356-3311 FAX:+82-31-356-5151 GREEN CROSS CORPORATION(110111-0109854) 303, BOJEONG-DONG, GIHEUNG-GU, YONGIN-SI,
GYEONGGI-DO, KOREA TEL:+82-31-260-9300 FAX:+82-31-260-9413 |
Related Parties
(Subsidiaries, Joint-Venture & Affiliates)
|
Affiliates |
DONGA PHARMACEUTICAL CO.,
LTD.(110111-0017990) DIGITAL OCEAN CO., LTD.(110111-1574874) SOO-SEOK CO., LTD.(110111-0107973) SOO-SEOK FARM CO., LTD.(164511-0016114) SOOSEOK INDUSTRIAL DEVELOPMENT CO.
LTD.(160111-0117790) DONG-A OTSUKA CO., LTD.(134111-0007761) KOREA SINTO CO., LTD.(130111-0010792) YONGMA LOGIS CO., LTD.(110111-0245369) SOO SEOK TRADING CO., LTD.(110111-0634231) DONG-A PHRAMTEC CO., LTD.(110111-2615578) DA INFORMATION CO., LTD.(110111-3479478) MOPEED CO., LTD.(110111-3372979) JIN-A GLASSES CO. D.A.C MOPEED AP MOPPED PHILIPPINES |
Sales by Region
(Activity & Markets)
Not Available.
Court Action
Not Available.
News Clipping
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.61 |
|
UK Pound |
1 |
Rs.75.32 |
|
Euro |
1 |
Rs.65.68 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.